Liquid biopsy in oncology refers to the use of a bio-fluid sample, such as blood, cerebrospinal fluid, or urine to detect and analyze biological markers to evaluate disease and determine cancer treatment options. This contrasts with a tissue biopsy, in which a small portion of a patient’s tumor is removed and analyzed for cancer biomarkers. Liquid biopsy can be used in conjunction with tumor tissue analysis, or as an alternative when a tissue biopsy is insufficient, unavailable, or not feasible. Liquid biopsies are typically conducted with blood as the sample type, and are used to identify cancer biomarkers in circulating tumor DNA (ctDNA) or on circulating tumor cells (CTCs), which are the most commonly evaluated indicators or drivers of cancer development. Doctors may use liquid biopsies to help design cancer treatment plans, to evaluate how well treatment is working, or to determine if a prior cancer condition has recurred. The ability to take multiple samples of blood may help doctors understand what kind of molecular changes are taking place over time in a patient’s tumor.
About the Liquid Biopsy Tests
Biocept’s liquid biopsy is performed on a simple blood sample. No complex surgical biopsy for tissue is required. Additionally, there is no radiation exposure like a CT Scan, PET/CT or X-Ray. No fasting is necessary prior to the test. Consult with your doctor on preparation for either procedure if you have questions.